Biosynex (ALBIO) - Total Liabilities

Latest as of June 2025: €105.13 Million EUR ≈ $122.91 Million USD

Based on the latest financial reports, Biosynex (ALBIO) has total liabilities worth €105.13 Million EUR (≈ $122.91 Million USD) as of June 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore ALBIO long-term asset investment ratio to see how much of total assets are deployed in long-term investments.

Biosynex - Total Liabilities Trend (2006–2024)

This chart illustrates how Biosynex's total liabilities have evolved over time, based on quarterly financial data. For the complete balance sheet picture, see how large is Biosynex's balance sheet.

Biosynex Competitors by Total Liabilities

The table below lists competitors of Biosynex ranked by their total liabilities.

Company	Country	Total Liabilities
Vereinigte Filzfabriken AG MU:VFF	Germany	€6.93 Million
Alta Zinc Limited F:8EE	Germany	€633.03K
Dataprep Holdings Bhd KLSE:8338	Malaysia	RM12.91 Million
Fusemachines Inc. Common stock NASDAQ:FUSE	USA	$22.11 Million
Clean Seas Seafood Limited F:C7S	Germany	€25.00 Million
Dhunseri Tea & Industries Limited NSE:DTIL	India	Rs4.36 Billion
123fahrschule SE DU:123F	Germany	€10.44 Million
Charm Engine KO:009310	Korea	₩842.27 Billion

Liability Composition Analysis (2006–2024)

This chart breaks down Biosynex's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. See ALBIO net asset quality index to measure how much of total assets are equity-financed.

Liquidity & Leverage Metrics

Key Metrics Explained

Metric	Value	Description
Current Ratio	2.41	Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities)
Quick Ratio	N/A	More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities)
Cash Ratio	N/A	Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities)
Debt to Equity	2.37	Measures financial leverage (Total Liabilities ÷ Shareholder Equity)
Debt to Assets	0.70	Portion of assets financed with debt (Total Liabilities ÷ Total Assets)

Liability Trends Comparison

This chart compares key liability metrics across different time periods, showing how Biosynex's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.

Annual Total Liabilities for Biosynex (2006–2024)

The table below shows the annual total liabilities of Biosynex from 2006 to 2024.

Year	Total Liabilities	Change
2024-12-31	€114.19 Million ≈ $133.50 Million	-2.74%
2023-12-31	€117.41 Million ≈ $137.27 Million	+25.96%
2022-12-31	€93.21 Million ≈ $108.98 Million	-7.84%
2021-12-31	€101.14 Million ≈ $118.24 Million	+69.17%
2020-12-31	€59.78 Million ≈ $69.89 Million	+252.37%
2019-12-31	€16.97 Million ≈ $19.84 Million	+66.35%
2018-12-31	€10.20 Million ≈ $11.92 Million	-12.10%
2017-12-31	€11.60 Million ≈ $13.57 Million	-23.39%
2016-12-31	€15.15 Million ≈ $17.71 Million	+122.01%
2015-12-31	€6.82 Million ≈ $7.98 Million	+103.94%
2014-12-31	€3.35 Million ≈ $3.91 Million	-0.24%
2013-12-31	€3.35 Million ≈ $3.92 Million	-8.63%
2012-12-31	€3.67 Million ≈ $4.29 Million	+297.02%
2011-12-31	€924.34K ≈ $1.08 Million	-1.96%
2010-12-31	€942.86K ≈ $1.10 Million	-2.39%
2009-12-31	€965.95K ≈ $1.13 Million	+32.14%
2008-12-31	€731.01K ≈ $854.63K	+47.38%
2007-12-31	€496.00K ≈ $579.88K	+16.98%
2006-12-31	€424.00K ≈ $495.70K	--

About Biosynex

PA:ALBIO France Medical Devices

Market Cap

$19.39 Million

€16.59 Million EUR

Market Cap Rank

#25945 Global

#425 in France

Share Price

€0.90

Change (1 day)

-1.10%

52-Week Range

€0.48 - €1.57

All Time High

€25.28